What is the Origin of Targeted Growth Hormone Secretagogues?

This therapeutic concept emerged from the discovery and subsequent pharmacological development of the Ghrelin/Growth Hormone Secretagogue Receptor (GHSR) system in the late 20th century. The term is a descriptor for a modern, sophisticated method of modulating the pituitary-hypothalamic axis. This strategy allows for a more natural physiological effect.

What is the Mechanism of Targeted Growth Hormone Secretagogues?

These agents function by binding to the GHSR, primarily in the pituitary, which mimics the action of the endogenous hormone Ghrelin, or by acting as an analog of Growth Hormone-Releasing Hormone (GHRH). This action stimulates the somatotroph cells to release stored GH in a natural, pulsatile fashion. The targeted nature ensures the integrity of the hormonal feedback loop is maintained as much as possible.

Targeted Growth Hormone Secretagogues ∞ Area

Targeted Growth Hormone Secretagogues

Meaning

A class of pharmaceutical agents, often peptides, designed to selectively stimulate the body’s natural release of endogenous growth hormone (GH) from the pituitary gland by acting on specific receptors. These secretagogues are ‘targeted’ because they aim to enhance the physiological, pulsatile release pattern of GH, avoiding the continuous, supraphysiological effects of exogenous GH administration. They represent a precision approach to metabolic and anabolic optimization.